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Cu(II) organizes b-2-microglobulin oligomers
but is released upon amyloid formation
KWASI ANTWI, MAURA MAHAR, RAPOLE SRIKANTH, MARK R. OLBRIS,
JULIAN F. TYSON, AND RICHARD W. VACHET
Department of Chemistry, University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
(R ECEIVED September 18, 2007; F INAL R EVISION January 2, 2008; ACCEPTED January 2, 2008)

Abstract
b-2-Microglobulin (b2m) is deposited as amyloid fibrils in the bones and joints of patients undergoing
long-term dialysis treatment as a result of kidney failure. Previous work has shown that biologically
relevant amounts of Cu(II) can cause b2m to be converted to amyloid fibrils under physiological
conditions in vitro. In this work, dynamic light scattering, mass spectrometry, and size-exclusion
chromatography are used to characterize the role that Cu plays in the formation of oligomeric intermediates that precede fibril formation. Cu(II) is found to be necessary for the stability of the dimer and
an initial form of the tetramer. The initially formed tetramer then undergoes a structural change to a state
that no longer binds Cu(II) before progressing to a hexameric state. Based on these results, we propose
that the lag phase associated with b2m fibril formation is partially accounted for by the structural
transition of the tetramer that results in Cu(II) loss. Consistent with this observation is the determination
that the mature b2m amyloid fibrils do not contain Cu. Thus, Cu(II) appears to play a catalytic role
by enabling the organization of the necessary oligomeric intermediates that precede b2m amyloid
formation.
Keywords: b-2-microglobulin; copper; amyloid; dialysis-related amyloidosis; mass spectrometry; dynamic
light scattering; size-exclusion chromatography

While protein amyloid fibril formation is associated with
human diseases such as Alzheimer’s, Parkinson’s, lightchain amyloidosis, type II diabetes, and many others
(Rochet and Lansbury Jr. 2000), the mechanisms by
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MS, mass spectrometry; ESI, electrospray ionization; DLS, dynamic
light scattering; ThT, thioflavin T; TEM, transmission electron microscopy; ICP, inductively coupled plasma; FESEM, field emission scanning electron microscope; SDS, sodium dodecyl sulfate; ppm, part
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which soluble proteins progress into insoluble amyloid
fibrils are still not clear. Understanding the mechanisms
of these processes has great importance not only for explaining these biological phenomena but also for rationally addressing these diseases.
b-2-Microglobulin (b2m) is a small protein (;12 kDa)
subunit of the class I major histocompatibility (MHC)
complex (Bjorkman et al. 1987). Upon turnover of the
MHC complex, the major fraction of b2m is normally
degraded in the kidney. While the plasma concentrations
in people with healthy kidneys are typically 1–3 mg/L,
elevated levels (10–60 times) of b2m can be found in
people suffering from kidney disease (Drüeke 2000;
Floege and Ketteler 2001). b2m is thought to be present
physiologically as a monomer; however, its amyloid
formation and subsequent deposition in joints and connective tissues are complications of severe renal failure

and long-term dialysis treatment, leading to a condition
referred to as dialysis-related amyloidosis (DRA). Elevated concentrations alone, though, are not sufficient
for conversion of b2m to amyloid fibrils. Other factors, caused presumably by the dialysis procedure, are
necessary.
While the exact factors that cause b2m fibril formation
in vivo are not known, several means exist to generate
b2m amyloid fibrils in vitro. b2m amyloid fibrils can be
generated under acidic conditions (pH < 3.6) (McParland
et al. 2000), by truncating the first six N-terminal amino
acids (Esposito et al. 2000), by dialyzing the protein into
distilled water followed by membrane drying (Connors
et al. 1985), by mixing the protein with collagen at pH ¼
6.4 (Relini et al. 2006), by sonicating the protein in the
presence of sodium dodecyl sulfate at pH ¼ 7.0 (Ohhashi
et al. 2005), and by incubating the full-length protein at
physiological conditions in the presence of stoichiometric
amounts of Cu(II) (Morgan et al. 2001; Eakin et al. 2002).
The latter method is intriguing and may have relevance to
the in vivo process because of the very near physiological
conditions used. Miranker and coworkers have argued
that the amount of Cu(II) in the dialysate may be sufficient for Cu(II) to play a causative role in b2m fibril
formation in vivo (Morgan et al. 2001; Eakin and
Miranker 2005). In a wider context, transition metals,
particularly Cu(II), have been found to associate with
proteins of several amyloid systems, including Ab of
Alzheimer’s disease (Bush and Tanzi 2002), a-synuclein
of Parkinson’s disease (Uversky et al. 2001), the prion
protein of Creutzfeldt-Jakob’s disease (Wadsworth et al.
1999; Jobling et al. 2001), and the immunoglobulin light
chains in light-chain amyloidosis (Davis et al. 2001).
These observations suggest that Cu(II) could play an
important general role in the amyloid formation of other
systems as well.
Because of the general role that Cu(II) could play in
amyloid formation and the specific role that it does play
in b2m amyloid formation in vitro, a greater understanding of the molecular features of copper’s association
with b2m prior to amyloid formation is important to
obtain. Previous results indicate that Cu(II)-induced b2m
amyloid formation involves structural as well as oligomeric changes prior to fibril formation (Eakin et al. 2004,
2006). Cu(II) was also very recently shown to cause the
oligomerization of b2m to a kinetically stable oligomeric form that does not contain Cu(II) (Calabrese and
Miranker 2007), suggesting that Cu(II) could play a
catalytic role in b2m fibril formation. In our work, we
have determined the temporal and stoichiometric progression of b2m oligomers. The role of Cu(II) in the
oligomeric changes that precede fibril formation is also
determined by resolving the Cu(II)-binding stoichiometries of specific oligomeric intermediates.

Results
Oligomerization of b2m
b2m fibril formation was stimulated using stoichiometric
amounts of Cu(II) under conditions almost identical to
those reported by Miranker and coworkers (Morgan et al.
2001; Eakin et al. 2002). Thioflavin T (ThT) binding,
sodium dodecyl sulfate (SDS) dissolution, and transmission electron microscopy (TEM) imaging were used
to confirm that amyloid formation occurred under the
incubation conditions in the presence of Cu(II). Upon
binding to amyloid-like species, the characteristic fluorescence spectrum of ThT changes (Naiki et al. 1989).
Figure 1 shows the ThT fluorescence enhancement upon
incubation of monomeric b2m with and without Cu(II).
The fluorescence signal produced by the Cu(II)-containing solution begins to increase very soon after Cu(II) is
added and levels off after about 1 h. No further increase
in the ThT fluorescence is observed even up to 4 d, when
the first insoluble material is observed, or after 1 wk when
the first indication of amyloid fibrils is seen by TEM.
Interestingly, as will be evident from the data below, the
shift in ThT fluorescence occurs as soon as a b2m dimer is
present in solution, which raises the question of ThT’s
utility as an indicator of the formation of b2m amyloid-like
species. In contrast, no ThT fluorescence enhancement is
observed in the control reaction [i.e., no Cu(II) present] for
any time point up to 1 wk. Moreover, no observable
insoluble material is formed in the absence of Cu(II) for
up to 2 mo. These results are consistent with those observed
previously and indicate that Cu is necessary to stimulate the
formation of amyloid-like species.
Another characteristic feature of amyloid-like aggregates as opposed to amorphous aggregates is that they
do not readily dissolve in 2% SDS. To test whether the
insoluble aggregates that are formed after 1-wk, 2-wk,

Figure 1. b2m amyloid formation monitored by thioflavin T (ThT)
fluorescence at 483 nm. The ThT fluorescence maximum shifts from
450 nm to 483 nm upon binding to amyloid-like structures, and the
fluorescence intensity at 483 nm increases in the presence of Cu (j) but
remains the same in the absence of Cu (d). The trend line associated with
the Cu data is from a sigmoidal fit of the data.

and 1-mo incubations with Cu(II) have this characteristic,
the aggregates were filtered and added to a 2% solution
of SDS at 37°C. In all the samples incubated for at least
1 wk, a visual assessment of the insoluble material
indicated that the aggregates did not dissolve after 24 h
in the presence of SDS, indicating that they were
amyloid-like aggregates. Finally, TEM images of the
aggregates were taken after incubation with Cu(II) for
different time periods (Fig. 2). After 1 wk (Fig. 2A) of
incubation, most aggregates do not have well-defined
structures, but a few do have straight morphologies. After
2 wk (Fig. 2B), most aggregates have curved and wormlike structures, and more straight fibrils are observed.
After 3 wk (Fig. 2C), most of the fibrils have long and
straight morphologies, which are hallmarks of amyloid
fibrils; however, some curved or worm-like structures are
also still observed. After 1 mo of incubation (Fig. 2D), the
vast majority of the fibrils are long and straight. Taken as
a whole, the ThT fluorescence measurements, SDS dissolution experiments, and TEM images suggest that the
aggregates formed during incubation with Cu(II) are
amyloid in nature. Thus, with proper incubation conditions that result in amyloid formation, further experiments were carried out to characterize the oligomeric
intermediates formed prior to fibril formation.
Characterization of oligomeric intermediates
Dynamic light scattering (DLS), mass spectrometry (MS),
and size-exclusion chromatography (SEC) were used to

Figure 2. Transmission electron micrograph images obtained from b2m
samples after incubation with Cu(II) for (A) 1 wk, (B) 2 wk, (C) 3 wk,
and (D) 4 wk. Dimensions of images A–C are 200 nm 3 325 nm, and
dimensions of image D are 500 nm 3 800 nm.

characterize the oligomeric intermediates that form prior
to fibril formation. These techniques are complementary
tools as they provide related information about oligomeric forms. Importantly, when data from these three
techniques are consistent, then confidence in the data
from each is increased. Results from each of these tools
led to two general observations about the oligomeric intermediates: (1) b2m forms dimers, tetramers, and hexamers;
(2) dimers, tetramers, and hexamers are measured in solution before amyloid fibrils are observed.
DLS data (Fig. 3) during the first 15 d of the incubation
with Cu(II) indicates that dimers, tetramers, hexamers,
and occasionally dodecamers are formed. A DLS measurement of a buffered solution of un-incubated monomeric b2m gives a radius of 2.0 nm, which compares
favorably with the estimated size of b2m in solution
(Verdone et al. 2002). As b2m is incubated in the presence of Cu(II), compounds with scattering distributions
centered at 2.3, 4.8, 8.7, 12.7, and 28.2 nm are observed
over time; however, the compound with a scattering
radius of 28.2 is not always observed. Also, a compound
with a radius of 55 nm, which would roughly have 24
b2m units, is occasionally observed, but it is excluded
from Figure 3 because it is rarely seen. Particles with
radii greater than 100 nm are also occasionally observed,
but these particles were usually ignored in the analyses
as they were most prevalent (and sometimes completely
dominated the signal) when samples were agitated too
much before the DLS measurement. A scattering radius
of 2.3 nm is similar to 2.0 nm, which suggests that this
compound is monomeric b2m. Given this radius for the
monomer, the compounds with radii of 4.8, 8.7, 12.7,
and 28.2 nm are likely dimers, tetramers, hexamers, and
dodecamers, respectively. Interestingly, no compounds
with radii corresponding to trimers, pentamers, heptamers, etc., are readily apparent. In summary, the DLS
data indicate that monomeric b2m first forms a dimer,
and then higher-order oligomers are formed via the
assembly of dimeric units.
Mass spectral data of Cu(II)-incubated samples up to
day 7 confirm that dimers, tetramers, and hexamers are
formed, while no odd numbered higher-order oligomers
are seen. Mass spectra of control samples up to 7 d only
show monomers (data not shown). Figure 4A is a representative electrospray ionization (ESI) mass spectrum
from a sample that was incubated for 5 d in the presence of Cu(II). The resolution in this spectrum is poor
because low-energy ESI source conditions were chosen to
minimize oligomer dissociation. Under these ion source
conditions many adducts from the desalted incubated
solution remain, and these adducts, which are mostly
due to ammonium acetate clusters, broaden the mass
spectral peaks for all the oligomers. Despite this peak
broadening, different oligomeric species can be identified

for the hexamers, other spectra were obtained under
higher-energy ESI conditions (e.g., Fig. 4B). This spectrum more clearly indicates the presence of dimers,
tetramers, and hexamers. Also, now present are peaks
that are consistent with a trimer and possibly a pentamer.

Figure 3. DLS analysis of b2m oligomer sizes after incubation with
Cu(II). (A) Scattering intensities as a function of radii for a Cu-b2m
sample incubated for 4 d. (B) Temporal progression of b2m oligomers for
the first 15 d of an incubation in the presence of Cu(II). Monomers (M),
dimers (M2), tetramers (M4), hexamers (M6), and dodecamers (M12) are
observed. The error bars represent the standard deviations from three
replicate measurements, except for the dodecamers, which were not
observed in all measurements. At days 13 and 15, particles with scattering
radii of >100 nm were consistently measured, but these species are not
included in this plot. The lines connecting the data points are not fits of the
data but are provided to simplify visualization of the data.

given that the molecular weight of monomeric b2m is
11,731. Peaks that appear at m/z ratios around 2135,
2350, and 2610 (labeled ‘‘M2’’) are the +11, +10, and +9
charge states of the dimer and confirm its presence. The
+11 and +9 charge states particularly identify these series
of peaks as dimers because monomers with these m/z
ratios would have the impossible charge states 5.5 and
4.5. Similarly, peaks at m/z ratios around 2760 (+17),
2940 (+16), 3130 (+15), and 3360 (+14) (labeled ‘‘M4’’)
indicate the presence of a tetramer. The presence of
hexamers is suggested by weakly abundant ions at m/z
ratios around 3705 (+19), 3915 (+18), and 4150 (+17)
(labeled ‘‘M6’’), but these data are not conclusive. Like
the DLS data, no consistent evidence for odd-ordered
oligomers is found in the mass spectral data for samples
incubated up to 7 d.
To improve the resolution of the spectrum and improve
our confidence in assigning the spectral peaks, especially

Figure 4. Mass spectral data for b2m incubated with Cu(II) after
desalting. (A) Mass spectrum obtained after a 5-d incubation, taken under
low-energy ESI source conditions. (B) Mass spectrum obtained after a
5-d incubation, taken under high-energy ESI source conditions. (C) Ion
abundances of b2m oligomers obtained over time. The ion abundance of
each oligomer is the sum of the peak areas for each charge state of that
oligomer. To account for day-to-day variability in the ion signal from the
ESI source, the mass spectrum of a 5 mM solution of ubiquitin was analyzed immediately before the incubated sample. b2m oligomer ion abundances were then normalized to the ubiquitin ion signals each day so that
the oligomer ion abundances could be compared from one day to the next.

Because these peaks are not apparent in other mass
spectra (days 1–7) taken under the low-energy ESI
conditions, we conclude that these peaks are artifacts
that arise from dissociation of some of the tetramers or
hexamers in the ESI source. Indeed, the trimer peaks are
not detected even under higher-energy ESI conditions
until day 3, and the potential pentamer peak is only observed at day 5. Thus, like the DLS data, the MS results
indicate that b2m oligomers are formed through the
building up of dimeric units. Figure 4C shows the
formation of the different oligomers over time as measured by MS. The data from this plot are roughly
consistent with the DLS data shown in Figure 3. In
particular, both sets of data show that dimers are formed
as soon as the measurements can be made, tetramers are
first formed after 24 h, and the hexamer is formed after
day 3. Considered together, the DLS and MS data indicate
that dimers, tetramers, and hexamers are all formed in
solution prior to observing insoluble material or b2m
fibrils.
SEC analyses indicate the presence of monomers, dimers,
tetramers, and higher molecular-weight oligomers when
incubated Cu-b2m samples are analyzed over the course of
2 wk (Fig. 5A,B). Based on comparison to a calibration
curve, the molecular weights of the compounds that have
elution times of 38, 35, and 29 min (Fig. 5A) are estimated
to be 11,730, 18,400, and 45,200, respectively. The compound(s) that have an elution time of 19 min have
molecular weights greater than or equal to 100,000. No
more precise information is available for these latter
compounds because they are at the exclusion limit for the
column. The expected molecular weight of the monomer is
11,731, which matches the molecular weight of the peak at
38 min, so this peak was assigned to the monomeric
protein. This assignment was also confirmed by online
SEC-MS analysis (data not shown). The estimated molecular weight of the peak at 35 min (18,400) is much less than
the expected molecular weight of the dimer (23,458);
however, online SEC-ESI-MS analysis confirmed that it
was the dimer (Fig. 5C). The peak at 29 min has an
estimated molecular weight of 45,200, which is about
10,000 more than the expected molecular weight of the
trimer and about 1700 less than the expected molecular
weight of the tetramer, which gives us good confidence that
this peak corresponds to the tetramer. Online SEC-ESI-MS
analysis confirms this assignment (data not shown) and
indicates that a small amount of hexamer co-elutes with the
tetramer as ions for this hexamer are measured. This
observation indicates that our SEC column is not efficient
enough to resolve the tetramer from the hexamer, suggesting that the hydrodynamic radii of the tetramer and
hexamer are similar. When compared to the DLS and MS
data, the intensities of the oligomers from the SEC analyses
are relatively low. In contrast to the DLS and MS data, the

Figure 5. SEC analysis of incubated b2m sample. (A) Example chromatograms for a control [i.e., no Cu(II)] sample (dotted line), a sample
incubated for 2 d with Cu(II) (thick line), and a sample incubated for 4 d
with Cu(II) (thin line). The inset shows an expanded region of the
chromatogram from 10 to 37 min. Monomers (M), dimers (M2), tetramers
(M4), and oligomers with molecular weights above 100,000 (Mn) are
observed. (B) Temporal progression of the oligomers measured by SEC.
The high molecular weight oligomers (Mn) are not included in this plot.
(C) SEC-ESI mass spectrum of the chromatographic peak eluting at
35 min, confirming that this compound is the b2m dimer. The charge state
of each mass spectral peak is labeled.

SEC measurements take place >25 min after the oligomers
have been removed from the incubated solution. Because
the oligomers are physically separated in SEC and are no
longer in equilibrium, they can dissociate before being

detected >19 min after injection. The reduced intensities
are then likely due to oligomer dissociation; however, the
data in Figure 5A do indicate that some fractions of the
oligomers are stable for >25 min.
Evolution of oligomers
Close examination of the DLS data (Fig. 3) reveals some
interesting aspects about the dynamics of the oligomer
formation. These data cannot be used to quantitatively
assess the relative amounts of each oligomer because
larger compounds scatter more light than smaller compounds. Even so, the temporal changes in the amount of
scattered light by each individual oligomer are insightful.
The oligomerization process occurs by first forming a
dimer, whose concentration becomes greatest around day
3. Tetramer is not observed until day 1, and its abundance
appears to increase as more dimer is formed. This observation and simple reason indicate that the dimer is a
necessary precursor to the formation of the tetramer. In
contrast, the tetramer is present for 2 or 3 d before the
hexamer is observed. The MS data show a similar result
(Fig. 4C). This observation implies that the tetramer is
initially incapable of progressing to the hexamer, but
something happens to the tetramer (e.g., a conformational
change) around day 3 that allows it to progress to a
hexamer. Once the hexamer is formed in solution, the
concentration of the dimer decreases to almost zero,
which suggests that the hexamer formation requires the
dimer. Accompanying the appearance of the hexamer
and the initial decrease in dimer concentration is the first
evidence of insoluble material. Furthermore, the first
evidence of amyloid-like fibrils by TEM occurs at 1 wk,
which coincides with the maximum hexamer concentration. These results might suggest that an oligomer just
larger than the hexamer is the unstable nucleus that
promotes fibril or protofibril formation. Additional evidence that supports this idea is the fact that octamers and
decamers are not observed in solution. The point at which
the concentration of hexamer is greatest in solution
(day 7) is also the point at which the concentration of
monomer sharply decreases and the concentration of
tetramer begins to level off. The leveling off of the
tetramer concentration may be explained by the need
for the tetramer to undergo a conformational change to
form a hexamer, as speculated above. This speculation
suggests that the tetramer has two forms, one that is
capable of progressing to a hexamer and one that is not.

were used to gather insight into Cu(II)’s association with
each oligomer. Cu appears to be necessary for the
stability of the dimer and the tetramer up to about day
5. This observation is apparent after 10 mM EDTA is
added to an aliquot of the incubation solution just before
SEC analysis. With the addition of EDTA, only the
monomer is observed by SEC up to day 5 (Fig. 6). This
result indicates that once Cu(II) is extracted from the
dimer and the tetramer, they are no longer stable (up to
day 5) and subsequently revert back to the monomer.
However, at day 5, some fraction of the tetramer peak
remains after reaction with EDTA. Even after allowing
EDTA to react with the sample for 60 min, this fraction
remains. Because the tetramer and hexamer co-elute in
SEC, MS of the EDTA-treated solutions was also performed; however, while the tetramer is observed by MS,
the low MS signal for the EDTA-treated samples does
not allow us to confidently conclude whether or not the
hexamer is still present (data not shown). Other recent
work on b2m reported a similar transition after about 5 d
(Calabrese and Miranker 2007); our work allows these
oligomers to be identified as tetramers, but we cannot rule
out the additional presence of hexamers. Thus, it appears
that there are two tetrameric forms: one requiring Cu(II)
and one that does not require Cu(II). This observation is
consistent with the data described in the previous section,
which suggested the presence of two forms of the tetramer: one that progresses to hexamer after day 4 and one
that continues to increase in concentration up to day 10
(Fig. 3). Finally, while removal of Cu causes the dimer
and tetramer to revert back to monomer, once fibrils are
formed, incubation with EDTA does not reverse the fibrils
back to monomers.
MS data confirm that the monomer, dimer, and
tetramer bind Cu(II). Expanded regions of the mass
spectra around the +7 charge state of the monomer, the

Role of Cu(II) in the stability of oligomeric intermediates
Cu(II) is clearly important for fibril formation, but its
specific role in the formation and stability of the oligomeric intermediates is important to assess. SEC and MS

Figure 6. SEC analysis of incubated b2m sample after the addition of
EDTA. Samples were incubated for the indicated time, and just prior to
analysis, an aliquot of the sample was reacted with 10 mM EDTA. The plot
shows data for the monomer (M), dimer (M2), and tetramer (M4).

+11 charge state of the dimer, and the +15 charge state of
the tetramer (Fig. 7A–C) show that these oligomers bind
up to 1, 2, and 4 Cu ions, respectively. These spectra are
expanded regions of the spectra acquired under higherenergy ESI source conditions (i.e., Fig. 4B). While the
peaks in Figure 7, B and C, are not fully resolved, the
high mass accuracy of the double-focusing mass spectrometer that was used increases our confidence in these
assignments. For example, the expected m/z ratio of the
+7 charge state of monomeric b2m is 1676.86, and that
of its Cu(II)-bound form is 1685.64. The experimentally measured m/z values for these ions are 1676.80
and 1685.57, respectively. Not only are these values very
close to the predicted values, they also confirm that

Figure 7. Expanded regions of the mass spectrum for a desalted solution
of incubated b2m obtained under high-energy ESI conditions. (A)
Expanded region around the monomer, indicating the binding of 0 and
1 Cu(II) ion. (B) Expanded region around the dimer, indicating the binding
of 0, 1, and 2 Cu(II) ions. (C) Expanded region around the tetramer,
indicating the binding of 0, 1, 2, 3, and 4 Cu(II) ions. In each spectrum the
numbers in parentheses are the m/z ratios of the corresponding ion.

Cu(II) and not Cu(I) is bound to the protein. Upon
binding to the protein, Cu(II) is expected to replace two
protons in order to maintain the same +7 charge state.
Cu(II) binding then should increase the mass of the
protein by 61.53 mass units (i.e., 63.55  2.02; because
the resolution in Fig. 7 is not high enough, the average
mass of Cu and H are used here). A mass increase of
61.53 will result in an m/z increase of 8.79 (or 61.53/7).
The observed m/z increase of 8.77 is thus very consistent
with the Cu(II) binding. Binding by Cu(I) would lead to
a m/z increase of 8.93. A similar evaluation can be done
for the dimer and tetramer shown in Figure 7, B and C,
and the measured m/z ratios for the relevant peaks are
shown in Fig. 7. In both cases, the relatively high mass
accuracies observed in these measurements confirm that a
maximum of two Cu(II) ions bind to the dimer and a
maximum of four Cu(II) ions bind to the tetramer.
Unfortunately, the low signal-to-noise ratios of the hexameric peaks and the significant adduct formation associated with these oligomers make it difficult to identify
whether the hexamer binds Cu(II). MS analyses of the
EDTA-treated samples indicate that the tetramer that
remains after day 5 does not contain Cu(II). To confirm
that Cu(II) binding to the b2m oligomers is specific and
not simply due to ESI-promoted adduct formation, ESI
mass spectra of lysozyme, which is a non-Cu-binding
protein, were investigated. Upon performing ESI-MS
under identical conditions from a desalted sample of
lysozyme, no Cu-lysozyme adducts are observed (data
not shown). Indeed, no Cu-lysozyme adducts are observed even up to 4:1 Cu:lysozyme ratios.
Further study of Cu binding to b2m was performed
by determining if the mature fibrils incorporate Cu. Two
sets of data indicate that Cu is not incorporated into the
mature fibrils. First, ICP-MS was used to determine the
concentration of Cu left in solution after 40 d of incubating b2m under fibril-forming conditions. After this
time period, >99% of the soluble protein had been converted into insoluble fibrils. The concentration of Cu
found in the remaining solution was 10.2 6 0.3 parts per
million (ppm), which is close to the expected 12.7 ppm
that would be found if no Cu was incorporated into the
fibrils. The remaining 2.5 ppm of Cu could be incorporated into the fibrils, but control experiments indicate that
the remaining Cu has precipitated as Cu(OH)2. Incubating
a b2m-free control sample for 40 d, in which all other
solution components were present, resulted in a solution
Cu concentration of 1.26 6 0.02 as measured by ICP-MS.
Clearly this concentration was much lower than the
expected 12.7 ppm and indicates that Cu had precipitated,
probably as Cu(OH)2. Indeed, a rinse of the control
sample tube with 5 M nitric acid resolubilized >95% of
the Cu. Equilibrium calculations confirm that the majority of Cu(II) is expected to precipitate as Cu(OH)2 in the

absence of the protein. Thus, we conclude that the 2.5
ppm of Cu that was not accounted for in the b2m incubated sample precipitates as Cu(OH)2 during the course
of the 40-d incubation. A much lower amount precipitated
(2.5 ppm) than was observed in the b2m-free control
sample, but this was most likely due to the fact that
soluble b2m, which was present for much of the incubation period, slowed precipitation of Cu.
A second experiment using X-ray microanalysis was
also performed on the fibrils themselves to determine if
Cu is incorporated into this insoluble material. Analysis
of a ;1 mg sample of the fibrils, after several rinses with
buffer, resulted in no measurable Cu. If all the solution Cu
had been incorporated into the solid fibrils, then 12.7 mg
would have been present. Even though the detection limit
for Cu has not been determined for the instrument that
was used, this concentration (i.e., 12,700 ppm) should be
readily measurable by X-ray microanalysis. X-ray microanalysis of biological samples typically provides detection limits between 100 and 500 ppm for most elements
and even lower limits for transition metals (Goldstein
et al. 1992). If the amount of Cu unaccounted for in the
ICP-MS experiments had been incorporated into the fibrils, then 2.5 mg (or 2500 ppm) would have been present.
Again, this concentration should be easily detectable by
X-ray microanalysis, so the failure to observe Cu indicates that it is not present in the fibrils.
Discussion
Characterizing reaction intermediates is essential for
more deeply understanding any chemical or biochemical
reaction, and this is no less true for amyloid fibrilforming reactions. The DLS, MS, and SEC experiments
reported here indicate that the formation of b2m fibrils
is preceded by the formation of oligomeric intermediates
that include dimers, tetramers, and hexamers. No oddordered oligomers appear to be precursors, and this
observation indicates that the oligomeric intermediates
form via the assembly of dimers. These observations are
consistent with previous results in which analytical ultracentrifugation was used to identify oligomers formed
prior to Cu-induced b2m fibril formation (Eakin et al.
2004). The results presented here provide higher resolution data confirming the presence of these even-ordered
oligomers, but our results also elucidate the Cu content of
these oligomers and indicate the temporal progression of
these oligomers. The formation of discrete oligomers as
prefibrillar intermediates has been observed for several
other amyloidogenic proteins, too (Walsh et al. 1997;
Friedhoff et al. 1998; Ferrao-Gonzales et al. 2005), and
indeed acid-induced (pH ¼ 2.5) amyloid formation of
b2m has been found to be preceded by dimers, trimers,
and tetramers (Smith et al. 2006). The fact that several

amyloidogenic proteins form oligomeric intermediates
prior to fibril formation may be important because the
oligomers themselves might be therapeutic targets for
preventing amyloid fibril formation. Indeed, at least in the
case of the amyloid b-protein of Alzheimer’s disease, oligomeric forms may represent the toxic form (Kirkitadze
et al. 2002).
In addition to confirming the presence of even-ordered
oligomeric intermediates prior to b2m fibril formation,
several experimental observations provide new insight
into Cu’s role in the formation of the prefibril oligomers.
First, MS data confirm that the +2 oxidation state of Cu
is the relevant state when complexed to the dimers and
tetramers. This may not be surprising as Cu(II) is added
to stimulate b2m fibril formation, but the absence of any
evidence for Cu(I) suggests that redox processes are
unlikely to play a role in the oligomerization and eventual
fibril formation of b2m. Oxidation can cause proteins
to aggregate, and any reduction of Cu(II) to Cu(I) would
likely result in protein oxidation. Not only do we not
detect Cu(II) reduction, but mass spectral data show no
increase in protein oxidation to the monomer or any of the
oligomers over the course of 7 d. As seen most clearly in
Figure 7A, the addition of a single oxygen atom to the
protein is observed, but the fraction of protein that is
oxidized remains at about 20%–30% from day 0 to day 7.
Furthermore, tryptic digestion of soluble b2m and peptide
sequencing by tandem MS indicate that only Met99 is
oxidized after incubations with Cu(II) for periods up to
7 d (J.D. Bridgewater and R.W. Vachet, unpubl.).
Second, Cu(II) binding is necessary for the stability of
the dimer and the initial form of the tetramer. Unfortunately, Cu(II)’s role in stabilizing the hexamer is unclear.
The importance of Cu for the stability of the dimer and
tetramer was obtained by sequestering Cu(II) at different
time points during the incubation and by measuring
Cu(II) complexes of these oligomers. Sequestering Cu(II)
in the b2m incubated sample was achieved by adding
an excess of EDTA. EDTA has a much higher affinity for
Cu(II) than that estimated for monomeric b2m (Morgan
et al. 2001), and given its relatively high concentration
(10 mM vs. 100 mM) it should completely sequester Cu
away from b2m and its oligomers. Upon removing Cu(II)
in this way, the dimer and tetramer completely dissociate
(cf. Figs. 5B and 6). These data indicate that the presence
of Cu(II) is necessary for the dimer and the tetramer to
form, but it does not definitively address whether Cu is
bound to the dimer and tetramer or whether simply access
to Cu by the monomer is necessary for these oligomers to
form. In other words, it is conceivable that Cu(II) binding
to the monomer allows b2m to reach a state that enables
formation of dimers and tetramers, but once forming this
state Cu(II) is released from the oligomers. In such a
scenario, sequestration of Cu(II) would simply shift the

equilibrium back to the monomeric state, and the oligomers would eventually disappear. The MS data (Fig.
7B,C) rule out this scenario, though, and provide evidence that Cu(II) binding to the dimer and tetramer is
necessary for their stability. The dimer and tetramer bind
up to two and four Cu(II) ions, respectively. These Cu(II)
ions are almost certainly bound specifically. Nonspecific
binding is precluded because the samples were desalted
prior to MS analysis, which would have removed uncomplexed Cu(II). Furthermore, analysis of lysozyme, which
does not bind Cu(II), under identical conditions results in
no measurable Cu adducts for this protein. The importance of Cu(II) for oligomer stability and the observation
of Cu(II)-specific binding to these oligomers indicate that
Cu(II) is required to maintain the intermolecular contacts
between the dimers and the initial form of the tetramers.
A third important observation is that after about 5 d of
incubation, some but not all of the tetramer remains after
Cu(II) is sequestered by EDTA (Fig. 6). Very recently it
was also reported that after a similar reaction time some
b2m oligomers appear to lose their requirement for Cu(II)
(Calabrese and Miranker 2007). Our results indicate that
this occurs with the tetramer. Furthermore, our results
indicate that there are two forms of the tetramer; one that
binds Cu and one that does not. Unfortunately, the Cu(II)binding status of the hexamer is unclear. As a likely
product of this second tetramer form, insight into the
Cu(II) content of the hexamer would be insightful.
Higher-resolution MS measurements will be needed to
determine directly whether or not Cu(II) binds to the
hexamer.
A fourth important set of experimental observations is
the temporal progression of the oligomers, which provides new information about the mechanism of b2m fibril
formation. The DLS data (Fig. 3) are particularly illustrative in this regard; however, the MS data are roughly
consistent with the DLS data. Close examination of the
concentration changes of the oligomers over time provides two new insights. First, the concentration change of
the tetramer over time is consistent with there being two
forms of this oligomer. Second, the failure to consistently
see soluble oligomers larger than the hexamer suggests
that an oligomer just larger than the hexamer might be the
unstable nucleus necessary for subsequent fibril formation. The key observations that support the idea of two
tetrameric forms are the differences in how the concentrations of the dimer, tetramer, and hexamers change over
time. The dimer forms before the tetramer (Figs. 3, 4C),
and it appears that, when the dimer’s concentration
reaches a maximum, the rate of tetramer formation is
the greatest (Fig. 3). These observations suggest that the
dimer is a necessary precursor of the tetramer and that the
tetramer begins to form as soon as dimer is present in
solution. In contrast, the hexamer does not form until day

3 or 4, which is 2–3 d after the tetramer first appears. This
observation may imply that the tetramer needs to go
through some structural transition before the hexamer can
form. This second form of the tetramer is also suggested
by the EDTA addition experiments with SEC. By SEC,
the second form of the tetramer, which does not bind Cu,
is not observed until day 5; failure to observe it at day 3
or 4 is most likely due to the limited sensitivity that the
SEC experiments have for the oligomers. An appealing
way to reconcile the DLS, MS, and SEC observations is
to speculate that the tetramer must reach a state in which
Cu(II) is no longer bound before converting to the
hexamer. The data further indicate that the tetramer’s
concentration continues to increase after the hexamer is
formed, and this might be due to the buildup of the first
tetramer that has not yet converted to the second tetrameric form that is required to progress to larger oligomeric species.
A second possible conclusion from the data in Figure 3
is that the nucleus necessary for subsequent fibril or
protofibril formation could be an oligomer just larger than
the hexamer. Nucleation-dependent aggregation is one
of the hallmarks of amyloid fibrillogenesis (Rochet and
Lansbury Jr. 2000), and oligomeric protein forms could
be possible seeds. In the present case, the hexamer could
be the largest stable oligomer possible before the formation of an unstable oligomeric nucleus ([b2m]n where
n > 6). An unstable oligomeric nucleus would not be
experimentally observed presumably because of its very
low steady-state concentration. Several observations support the idea of a nucleus that is just larger than the
hexamer: (1) No octamers or decamers are observed, and
only occasionally are dodecamers observed, which may
form from the infrequent annealing of two hexamers; (2)
the first indication of insoluble material occurs after 4 d
of incubation, which coincides with the appearance of the
hexamers in solution; (3) the first definitive evidence for
amyloid-like fibrils occurs after 1 wk, which is when the
hexamer concentration is at a maximum; (4) a significant
drop in the concentrations of monomers and dimers in
solution occurs upon the formation of the hexamers,
presumably indicating a rapid conversion of soluble
monomers and dimers into insoluble oligomer/aggregates
after a species just larger than the hexamer is formed.
While these experimental data suggest that the nucleus
could be an oligomer just larger than the hexamer, more
careful kinetic studies are needed to further confirm this
hypothesis.
Proposed model for b2m fibril formation
The data presented here allow a more detailed model of
Cu(II)-induced b2m fibril formation to be proposed (Fig.
8). In b2m, His31 (Eakin et al. 2002; Lim and Vachet

2004), the N-terminal amine (Lim and Vachet 2004), and
possibly an amide nitrogen between Ile1 and Gln2 (Lim
and Vachet 2004) comprise the Cu(II) binding site at
pH ¼ 7.4, although Cu(II) binding to His13 and His51
have also been suggested at lower pH values (Verdone
et al. 2002; Villanueva et al. 2004). Both urea and thermal
denaturation studies indicate that the conformational
stability of b2m is lower in the presence of Cu(II)
(Morgan et al. 2001; Eakin et al. 2002). Thus, Cu(II)
destabilizes monomeric b2m (Fig. 8, 1) and causes it
to form a dimer (Fig. 8, 2) and subsequently tetramer A
(Fig. 8, 3). The exact nature of the conformational change
necessary for initial oligomer formation has not been
determined for the wild-type protein, but it has recently
been suggested that a cis-trans isomerization involving
Pro32 caused by nearby Cu(II) is the necessary conformational change that allows oligomerization (Eakin et al.
2006). The same conformational change has been suggested to be a direct precursor for fibril elongation of
b2m as well (Jahn et al. 2006). Furthermore, it has been
suggested that b2m oligomers are formed via a domainswapping mechanism (Eakin et al. 2004, 2006; Eakin and
Miranker 2005). From the data presented here, the
importance of Cu(II) to the stability of the dimer and
tetramer A is evident from the experiments involving
EDTA, which demonstrate these oligomers can revert
back to monomers if Cu(II) is removed. A key step in the
eventual formation of fibrils or protofibrils is the conversion of tetramer A into tetramer B (Fig. 8, 4). The
EDTA-addition experiments and the absence of Cu in
the mature fibrils suggest that this conversion occurs via
the loss of Cu(II). Evidently, stepwise association of b2m
molecules provides the necessary energy to overcome the
enthalpic penalty of Cu(II) dissociation. Conversion to
tetramer B then allows the formation of the hexamer (Fig.
8, 5). Our data do not indicate the oligomeric species that
combines with tetramer B to form the hexamer, but the
absence of any pentamers or octamers might suggest the

involvement of a dimer. Once the hexamer is formed,
we hypothesize that a slightly larger oligomer acts as the
nucleus (Fig. 8, 6) that enables fibril or protofibril formation (Fig. 8, 7).
If correct, then there are three important implications
of this model. First, b2m amyloid formation is preceded
by discrete oligomeric intermediates. Further structural
characterization of these intermediates, especially the two
tetrameric forms and the hexamer, may identify rational
strategies to prevent b2m fibril formation. Second, this
model suggests that formation of the nucleus is not
completely responsible for the lag phase observed with
fibril formation of b2m. A structural transition [i.e.,
Cu(II) loss] by a prior intermediate accounts for some
of the lag phase. Third, Cu(II) is only necessary for
nucleation and is released from b2m upon fibril formation. This observation indicates that biologically relevant
concentrations of Cu may be sufficient for b2m fibril
formation in vivo. Significant concentrations of Cu(II) in
joint spaces of dialysis patients may not be necessary to
cause b2m fibril formation at these sites. Instead, interactions between b2m and Cu(II) at other locations (e.g.,
dialysate) may be sufficient to form the nucleus that is the
necessary precursors to fibrils.
Materials and Methods
Materials
Wild-type b2m was obtained from Fitzgerald Industries International, Inc. The protein was purified by ultrafiltration with
Centricon 10,000 molecular-weight cutoff centrifuge tubes (Millipore Corp.) prior to use. Urea and nitric acid were obtained from
Mallinckrodt Baker, Inc. 3-(N-morpholino)propanesulfonic acid
(MOPS) and all other proteins were obtained from Sigma-Aldrich.
All other chemicals were obtained from Fisher Scientific. Deionized water from a Millipore Simplicity 185 water purification
system was used for all sample preparations.

Formation of b2m fibrils
To obtain the amyloid fibrils of b2m, a sample solution
containing 100 mM b2m, 200 mM copper(II) sulfate, 200 mM
potassium acetate, 500 mM urea, and 25 mM MOPS (pH 7.4)
was incubated at 37°C. Control experiments without Cu(II) were
also performed in which a solution containing 100 mM b2m, 10 mM
ethylenediamine tetraacetic acid (EDTA), 200 mM potassium
acetate, 500 mM urea, and 25 mM MOPS (pH 7.4) was also
incubated at 37°C. EDTA was added to ensure no association
between trace amounts of Cu(II) and the protein.

Size-exclusion chromatography

Figure 8. Proposed model for the role of Cu(II) and b2m oligomers in
amyloid fibril formation.

The compounds present in incubated solutions of b2m were
separated using a Superdex 75 PC 3.2/30 column (Amersham
Biosciences) installed on an HP 1100 series high-performance
liquid chromatography system (Agilent). Before analysis of the

sample, the SEC column was first equilibrated with a 20 mM
ammonium acetate mobile phase (pH ¼ 7.4) at a 0.04 mL/min
flow rate for 1 h. During the analysis, 5 mL of an incubated
sample solution was injected into the sample loop. A variablewavelength detector set at 280 nm was used for detection. For
the molecular weight (MW) calibration, a solution containing a
mixture of the following proteins and peptides was used: 1.5 mM
bovine serum albumin (MW ¼ 66,000), 3 mM carbonic
anhydrase (MW ¼ 29,040), 3 mM b2m (MW ¼ 11,731), and
30 mM angiotensin I (MW ¼ 1296). For online SEC-ESI-MS
experiments, 20 mL of sample was injected onto the column.
The high-energy MS source conditions, which are described
below, were used for these online analyses.

Desalting
Desalting experiments were performed using a 5-mL HiTrap
desalting column from Amersham Biosciences that had an
exclusion limit of 5000 Da. The column was first equilibrated
with 30 mL of the mobile phase (10 mM ammonium acetate,
pH 7.4). Then, 100 mL of the incubated sample was injected onto
the column via a sample loop attached to a homemade setup.
The desalted b2m sample was eluted at a flow rate of 5 mL/min
using 10 mM ammonium acetate (pH 7.4), which was filled into
a syringe and delivered by a peristaltic pump. About 20 s after
injection of the sample, ;1.0 mL of the b2m fraction eluting
from the column was collected and then analyzed within ;2 min
by ESI-MS. Not only did the desalting column remove excess
salt that would compromise subsequent ESI-MS analyses, but
it also reduced the total concentration of the protein to less than
10 mM, which was important for minimizing nonspecific complex formation during the ESI process.

interrogated by DLS, the sample was centrifuged at 14,000g for
8 min prior to analysis.

Thioflavin T fluorescence
Fluorescence experiments were performed using a QuantaMaster
4 SE spectrofluorometer (Photon Technology International). A
solution containing 100 mM b2m, 80 mM ThT, 500 mM urea,
25 mM MOPS, and 200 mM potassium acetate was initially equilibrated at 37°C, and after addition of 200 mM CuSO4, the
fluorescent enhancement of ThT was measured. Measurements
were taken at excitation and emission wavelengths of 437 and 483
nm, respectively.

Transmission electron microscopy (TEM)
TEM images were obtained on a JEOL JEM-100CX electron
microscope operating at 100 keV. Before analysis, a solution
containing insoluble material was centrifuged (14,000g) for
8 min and decanted, and the solid material was resuspended in
10 mL of the supernatant. The resulting solution was then applied
to carbon-coated copper grids and allowed to air-dry for 5 min.
The sample was then stained with 1% phosphotungstic acid, airdried for 12 h, and then viewed.

Inductively coupled plasma mass spectrometry

A JMS-700 MStation (JEOL) double-focusing mass spectrometer equipped with a standard ESI source was used to acquire
all mass spectra. Two different ESI source conditions were used.
For the low-energy source conditions, the following settings were
used: desolvating plate temperature, 100°C; orifice temperature,
140°C; orifice potential, 0 V; ring lens potential, 100 V. For the
high-energy source conditions, the following settings were used:
desolvating plate temperature, 100°C; orifice temperature, 140°C;
orifice potential, 60 V; ring lens potential, 100 V.

Copper was determined with an ELAN DRC-e (PerkinElmer
Instruments) ICP mass spectrometer, equipped with a crossflow nebulizer, a Scott-type double-pass spray chamber, and a
quadrupole mass filter. The instrument was used in peak
hopping mode, with ;0.05 s residence time per mass, and a
total analysis time of 1.24 min per run. Flow injection was used
to introduce an incubated b2m sample for analysis. The sample
injection volume was 150 mL. Working standard solutions of
copper, obtained by serial dilution from a stock solution, were
prepared in 1% sub-boiled nitric acid. A 1000 mg/L stock
solution of Cu(II) was prepared by dissolving 0.1965 g of
CuSO4  5H2O in 50 mL 1% nitric acid. The reported measurements were obtained using a gallium internal standard. The
internal standard was prepared from a stock solution of 1 mg/L
gallium in 1% nitric acid, which was obtained from 0.5 mL of a
1000 mg/L atomic absorption standard solution (Ricca Chemical Co.).

Dynamic light scattering (DLS)

X-ray microanalysis

DLS studies were conducted using a Zetasizer Nano-ZS instrument (Malvern Instruments). The intensity of the scattered laser
was measured by optics placed at 173°. Measurements were
performed using 45 mL of incubated sample. Before analysis of
each sample, the device was pre-equilibrated at 37°C for 5 min
and was maintained at this temperature throughout the experiment. Every sample was measured five times for 0.5 min each,
and at least three replicate measurements were performed for
each incubation time point. The CONTIN algorithm was used to
fit the resulting intensity correlation curves as multi-exponentials.
Essential to the success of these measurements was careful transfer of the incubated sample into the DLS instrument. Excessive
agitation of the sample prior to analysis resulted in the data being
completely dominated by particles with diameters >100 nm. To
minimize the suspension of insoluble material in the solutions

A JEOL 6320 FXV field emission scanning electron microscope
(FESEM) was used for the X-ray microanalysis experiments
on b2m fibrils. This FESEM instrument is equipped with a BE
(backscattered) detector and a thin-window energy-dispersive
X-ray spectrometer from Princeton Gamma-Tech, which enables
X-ray microanalysis on sub-micrometer-sized samples. The
voltage used in the analysis of the b2m fibrils was 10 kV, the
tilt angle was 20°, and the beam current was 8 mA. b2m fibrils
were washed several times with buffer before X-ray analysis.

Mass spectrometry
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